Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Central obesity measured by waist-to-hip ratio independently predicts crohn's disease risk: a prospective cohort study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [London] : BioMed Central, 2002-
    • الموضوع:
    • نبذة مختصرة :
      Objective: This study evaluated associations between several obesity indicators and the risks of Crohn's disease (CD) and ulcerative colitis (UC), the two principal clinical phenotypes of inflammatory bowel disease (IBD).
      Methods: Data from 479,590 UK Biobank participants (mean age ± standard deviation: 56.5 ± 8.09 years; 54.5% female) were analyzed. Participants were classified based on waist circumference (WC). Cox proportional hazards models were used to quantify associations between multiple adiposity measures and incident CD and UC, adjusting for demographic, behavioral, and clinical covariates.
      Results: During a median observation period of 12.5 years (maximum 15.6 years), 1,518 incident CD cases and 2,957 incident UC cases were identified. Taking into account demographic variables (age, sex, and ethnic background), lifestyle indicators (including smoking, alcohol intake, sleep, diet, physical exercise, and employment), socioeconomic status measured by the Townsend Deprivation Index(TDI), coexisting conditions (hypertension and diabetes), inflammatory status (C-reactive protein), and nonsteroidal anti-inflammatory drug consumption, waist-to-hip ratio (WHR)-defined central adiposity was found to elevate the risk of CD (hazard ratio [HR] 1.18; 95% confidence interval [CI] 1.05-1.34). However, WC-defined central obesity did not demonstrate a statistically significant link to CD risk (HR 1.11, 95% CI 0.97-1.27). In minimally adjusted models, WHR-defined central obesity was associated with an increased hazard of UC (HR 1.13; 95% CI 1.05-1.23); this association attenuated to non-significance after full covariate adjustment (HR 1.03; 95% CI 0.95-1.13). Obesity defined by BMI ≥ 30 showed no relation to CD, whereas it was associated with a lower hazard of UC (HR 0.86; 95% CI 0.78-0.95). Similarly, higher body-fat percentage (BFP: male > 25%, female > 35%) was associated with a modestly lower hazard of CD (HR 0.92; 95% CI 0.85-0.99). Excluding incident IBD events that occurred during the first 24 months of follow-up, the WHR-CD association persisted (HR 1.19; 95% CI 1.04-1.36). Additionally, individuals in the highest third of WHR-for-BMI residuals (> 66th percentile) exhibited a markedly elevated risk of CD (HR 1.26; 95% CI 1.10-1.44).
      Conclusions: Central obesity, assessed by WHR, independently predicts the risk of CD, with a particularly pronounced effect in females, irrespective of BMI or other metabolic confounders. Conversely, higher BMI and BFP were inversely associated with UC risk.
      (© 2025. The Author(s).)
    • نبذة مختصرة :
      Declarations. Ethics approval and consent to participation: The UK Biobank has been approved as a Research Tissue Bank (RTB) by the North West Multicenter Research Ethics Committee (MREC) under ID: 11/NW/0382. All participants provided written informed consent prior to their involvement in the study, which adhered to the principles outlined in the Declaration of Helsinki. This RTB approval allowed researchers to conduct their work without requiring additional ethical permissions. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
    • References:
      Inflamm Bowel Dis. 2015 Feb;21(2):361-8. (PMID: 25563694)
      Gut. 2012 Jan;61(1):78-85. (PMID: 21940721)
      World J Mens Health. 2020 Jan;38(1):48-60. (PMID: 30929328)
      Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. (PMID: 33356944)
      Inflamm Bowel Dis. 2011 Oct;17(10):2162-8. (PMID: 21910178)
      Healthcare (Basel). 2021 Jan 03;9(1):. (PMID: 33401588)
      J Crohns Colitis. 2021 Sep 25;15(9):1474-1480. (PMID: 33609363)
      Nutrients. 2022 Sep 25;14(19):. (PMID: 36235636)
      Lancet. 2005 Nov 5;366(9497):1640-9. (PMID: 16271645)
      Clin Gastroenterol Hepatol. 2023 Aug;21(9):2211-2221. (PMID: 35863682)
      Int J Colorectal Dis. 2015 Feb;30(2):237-42. (PMID: 25392256)
      Obes Rev. 2024 Jun;25(6):e13724. (PMID: 38408757)
      BMJ Open. 2024 Mar 7;14(3):e074659. (PMID: 38453206)
      Arthritis Res Ther. 2015 Feb 13;17:32. (PMID: 25888974)
      Biol Sex Differ. 2012 May 31;3(1):13. (PMID: 22651247)
      Gastroenterology. 2006 Sep;131(3):853-61. (PMID: 16952554)
      Inflamm Bowel Dis. 2015 Dec;21(12):2857-63. (PMID: 26241001)
      Dig Dis Sci. 2015 Aug;60(8):2436-45. (PMID: 25799938)
      Inflamm Bowel Dis. 2019 Jan 10;25(2):283-293. (PMID: 30295909)
      Clin Gastroenterol Hepatol. 2022 May;20(5):1048-1058. (PMID: 34242756)
      Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: 33921758)
      Inflamm Bowel Dis. 2014 Dec;20(12):2286-91. (PMID: 25222655)
      Gastroenterology. 1999 Jul;117(1):73-81. (PMID: 10381912)
      Biomolecules. 2019 Nov 26;9(12):. (PMID: 31779136)
      Immunity. 2007 Feb;26(2):241-55. (PMID: 17307705)
      World J Gastroenterol. 2016 Sep 21;22(35):7868-81. (PMID: 27672284)
      Braz J Med Biol Res. 2012 Jul;45(7):591-600. (PMID: 22510779)
      Am J Gastroenterol. 2013 Apr;108(4):575-82. (PMID: 23318483)
      PLoS One. 2011;6(10):e26621. (PMID: 22028926)
      Cell Mol Gastroenterol Hepatol. 2015 Jul 1;1(4):420-432. (PMID: 26543894)
      Am J Gastroenterol. 2018 May;113(5):694-701. (PMID: 29535417)
      Eur J Immunol. 2015 Sep;45(9):2446-56. (PMID: 26220361)
      Endocr Rev. 2000 Dec;21(6):697-738. (PMID: 11133069)
      J Biol Chem. 2017 Apr 21;292(16):6569-6582. (PMID: 28258220)
      Diabet Med. 2006 May;23(5):469-80. (PMID: 16681555)
      Int J Epidemiol. 2014 Jun;43(3):843-55. (PMID: 24609069)
      Dig Dis Sci. 2017 Dec;62(12):3280-3286. (PMID: 29086333)
      Front Immunol. 2014 Sep 24;5:462. (PMID: 25309544)
      World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253. (PMID: 11234459)
      Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121. (PMID: 27899815)
      J Crohns Colitis. 2023 May 3;17(5):681-692. (PMID: 36562457)
      Obes Rev. 2019 Sep;20(9):1312-1320. (PMID: 31190427)
      Inflamm Bowel Dis. 2024 Apr 3;30(4):594-601. (PMID: 37307420)
      Circulation. 2008 Apr 1;117(13):1658-67. (PMID: 18362231)
      Aliment Pharmacol Ther. 2020 Jun;51(11):1067-1075. (PMID: 32319111)
    • Grant Information:
      2021ZA107 Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project; ZA_CACM_2024002 Clinical Research Project of the China Association of Chinese Medicine; A20230658 Hangzhou Health and Health Commission; 2024ZR121 Provincial Central Management Bureau Heritage Innovation Talent Project
    • Contributed Indexing:
      Keywords: Body mass index; Central obesity; Crohn disease; Ulcerative colitis; Waist-to-Hip ratio
    • الرقم المعرف:
      9007-41-4 (C-Reactive Protein)
    • الموضوع:
      Date Created: 20251030 Date Completed: 20251030 Latest Revision: 20251101
    • الموضوع:
      20260130
    • الرقم المعرف:
      PMC12573991
    • الرقم المعرف:
      10.1186/s12944-025-02763-8
    • الرقم المعرف:
      41163157